Contents hide 1 Non-Small Cell Lung Cancer 2 Dosage Modifications 2.1 Dosage reduction levels for adverse reactions Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. Non-Small Cell Lung Cancer Indicated for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults who have received ≥1 prior systemic therapy 960 mg PO qDay Continue until disease progression or unacceptable toxicity Dosage Modifications Dosage reduction levels for adverse reactions First dose reduction: 480 mg qDay Second dose reduction: 240 mg qDay Unable … Continue reading Generic (Sotorasib) SOTOLDX